Alison Cecily Finger
CIK 1731164 · Chief Commercial Officer · last filed 2026-02-11
Alison Cecily Finger is a Chief Commercial Officer who has filed 24 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing, for ADMA, was dated Feb 11, 2026. Across all open-market trades the lifetime net is −$439.7K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $502.3K across reported positions. 18 SEC filings were submitted jointly with bluebird bio, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BLUE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
60 BINNEY STREET
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ADMA | Director | 45,619 | $11.01 | $502.3K | $0 | 3 | 2026-02-11 |
| Decibel Therapeutics, Inc. (DBTX) Delisted | Director | 0 | $4.91 | $0 | $0 | 4 | 2023-09-25 |
| bluebird bio, Inc. (BLUE) Delisted | Chief Commercial Officer | 1,293 | $4.97 | $6.4K | -$439.7K | 17 | 2021-01-08 |
Recent Filings
24 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-11 | ADMA | Grant (A) | +10,690 | $0 | EDGAR |
| 2025-02-21 | ADMA | Grant (A) | +10,889 | $0 | EDGAR |
| 2024-02-28 | ADMA | Grant (A) | +24,040 | $0 | EDGAR |
| 2023-09-25 | Decibel Therapeutics, Inc. (DBTX) Delisted | Disp (D) | −5,000 | $0 | EDGAR |
| 2023-06-14 | Decibel Therapeutics, Inc. (DBTX) Delisted | Grant (A) | +5,000 | $0 | EDGAR |
| 2022-06-21 | Decibel Therapeutics, Inc. (DBTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-12-06 | Decibel Therapeutics, Inc. (DBTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-08 | bluebird bio, Inc. (BLUE) Delisted | Sell (S) | −1,854 | -$83.5K | EDGAR |
| 2020-12-04 | bluebird bio, Inc. (BLUE) Delisted | Sell (S) | −36 | -$1.7K | EDGAR |
| 2020-11-04 | bluebird bio, Inc. (BLUE) Delisted | Sell (S) | −35 | -$1.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.